

**CANCER FUND Invests in AOA Dx, Inc. to Revolutionize Women's Health
Diagnostics**

*AOA Dx pioneering innovative biomarker technology to enable earlier detection of
ovarian cancer*

Phoenix, AZ, October 12, 2023 – CANCER FUND is excited to announce its investment in AOA Dx, Inc. (AOA), an innovative company in women's health diagnostics. The investment represents CANCER FUND's fourth investment out of Cancer Fund I and becomes its third portfolio company in pursuing its mission to support cancer innovators progress from lab to patient care.

"We're thrilled to invest in AOA and the further development of their technology aiming to enable earlier diagnosis of Ovarian cancer. It offers the potential to make early detection of Ovarian cancer in patients faster, at early cancer stage-which is critical in cancers without early symptoms and as deadly as Ovarian cancer. We believe AOA's testing could save lives and improve the survival of women worldwide," said CANCER FUND Managing Director Anthony Bajoras. "AOA exemplifies the type of innovators that CANCER FUND was created to support, we're proud to see our community members join together to make this investment."

AOA is developing a groundbreaking biomarker technology platform centered on tumor glycolipids. The primary objective is to detect early-stage Ovarian cancer by quantifying circulating gangliosides, addressing a critical unmet need in women's health. Alarming, 80% of women diagnosed with Ovarian cancer are currently diagnosed at advanced stages (III and IV), leading to a distressing five-year survival rate of only 28%. AOA's revolutionary AKRIVIS GDT^M is a non-invasive "liquid biopsy" blood test that has the potential to save up to 100,000 women's lives annually, a large population that also represents a sizable market opportunity. With a pivotal multicenter clinical validation study and a stellar team, AOA Dx, Inc. is poised to usher in a brighter future for women's health diagnostics.

"AOA is honored to add Cancer Fund I as an investor. We've valued working with CANCER FUND's unique community-driven model and their mission of supporting innovative companies on the path to bring better access to cancer care," said AOA Dx CEO Oriana Papin-Zoghbi, PhD..

About CANCER FUND:

CANCER FUND is a community of impact investors committed to advancing cancer care, fostering innovative solutions, and enhancing the lives of cancer patients, survivors, and previvors. Through collaboration with a diverse community of over 2,300 members, including patients, survivors, caregivers, healthcare professionals, and impact investors, CANCER FUND is currently investing out of Cancer Fund I dedicated to driving significant change in the fight against cancer. To learn more about how you can become part of our investor community, visit www.cancerfund.com.

About AOA Dx, Inc.:

AOA Dx, Inc. stands as a pioneering company leading the charge in women's health diagnostics. Anchored in its proprietary biomarker technology platform, which revolves around glycolipids and the Tumor Ganglioside Matrix, AOA Dx, Inc. aims to revolutionize early cancer detection. With a specific focus on Ovarian cancer, the company is unwavering in its commitment to saving lives and improving outcomes for women grappling with this devastating disease.

Disclaimer

Contents of this release are provided for general information purposes only and do not constitute an offer to sell or a solicitation of an offer to buy any security of CANCER FUND or its affiliates in any jurisdiction. CANCER FUND does not intend to solicit and IS not soliciting, any action with respect to any Security or any other contractual relationship. Nothing in this release or the contents thereof, individually or taken in the aggregate, constitutes an offer of securities for sale or a solicitation of an offer to buy any security in the United States or in any other jurisdiction in which such an offer or solicitation is unlawful.

Forward Looking StatementsWhen used herein, the words “anticipate”, “believe”, “could”, “estimate”, “expect”, “going forward”, “intend”, “may”, “ought to”, “plan”, “project”, “seek”, “should”, “will”, “would” and similar expressions, as they relate to CANCER FUND, CANCER FUND affiliates including Cancer Fund I, LLC, CANCER FUND’s management, or any of their actual or prospective investments, are intended to identify forward-looking statements. These forward-looking statements reflect CANCER FUND’s views at the time such statements were made with respect to future events and are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known,-unknown, and unknowable risks and uncertainties. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including any changes in the laws, rules and regulations relating to any aspects of-CANCER FUND’s or its affiliates business operations, general economic, market and business conditions, including capital market developments, changes or volatility in interest rates, foreign exchange rates, equity prices or other rates or prices, various business opportunities that CANCER FUND may or may not pursue, changes in population growth and other demographic trends, including mortality, morbidity and longevity rates, persistency levels, CANCER FUND’s ability to identify, measure, monitor and control risks in CANCER FUND’s business, including its ability to manage and adapt its overall risk profile and risk management practices, and seasonal fluctuations and factors beyond CANCER FUND’s control. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. CANCER FUND undertakes no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise.